NCT05130866 2025-10-07
POPLAR-NF2
Recursion Pharmaceuticals Inc.
Phase 2/3 Terminated
Clinical Trials
4 trialsNCT02569320 2021-06-15
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT01798901 2018-03-14
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed